Get informed when a big investor buys or sells
+ FollowOvervalued by 49.7% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.15 Billion |
|---|---|
| Enterprise Value | $1.12 Billion |
| Annual dividend | $2.46 |
| Dividend yield | 3.41% |
| Earnings per Share | $-0.23 |
| Beta | 1.49 |
| Outstanding Shares | 17,042,708 |
| P/E Ratio | -162.78 |
|---|---|
| PEG | -119.34 |
| Price to Sales | 4.21 |
| Price to Book Ratio | 2.04 |
| Enterprise Value to Revenue | 3.94 |
| Enterprise Value to EBIT | 21.86 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that...